Blindness News and Research

RSS

Rubella epidemic played a major role in shifting public attitudes toward abortion laws

Ten years before the 1973 Supreme Court decision legalizing abortion - which likely will be a focus of Senate confirmation questions for Supreme Court nominee Elena Kagan next week - German measles probably played the biggest part in starting to shift public attitudes about the criminal abortion laws, University of Illinois historian Leslie J. Reagan says in a new book.

29 Jun 2010

Sunridge International delivers 60 PNT Units and 10,000 disposable rings to BV of China

Sunridge International, announced today that it has completed production and delivery of 60 PNT Units and 10,000 disposable rings to its exclusive distributor, Beijing Vision World Trading Company (BV) of China.

28 Jun 2010

UCSB, Sansum achieve milestone in JDRF funded Artificial Pancreas Project

The University of California Santa Barbara (UCSB) and Sansum Diabetes Research Institute (Sansum) announced today the achievement of a milestone in the Artificial Pancreas Project funded by the Juvenile Diabetes Research Foundation (JDRF).

28 Jun 2010

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

Raptor Pharmaceutical Corp. announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

28 Jun 2010

In-school education programs can reduce obesity, other risk factors for type 2 diabetes: HEALTHY

Healthier cafeteria choices, longer and more intense periods of physical activity and robust in-school education programs can lower rates of obesity and other risk factors for type 2 diabetes, according to a national study called HEALTHY.

28 Jun 2010

HQC report presents different aspects of health care delivered in Saskatchewan hospitals

There's been little change over the last three years in how patients rate the care they receive in Saskatchewan hospitals, according to a report released today by the province's Health Quality Council. The report, entitled Quality Insight 2010, presents an overview of aspects of quality of care delivered in hospitals, in the community for people living with certain chronic diseases, and for seniors taking prescription drugs.

25 Jun 2010

NKI awarded Phase II SBIR grant to develop new ophthalmic screening device for diabetic retinopathy

Neuro Kinetics, Inc., manufacturers of noninvasive medical diagnostic equipment used worldwide to test for vestibular and neurological conditions, said today that it has been awarded a Phase II Small Business Innovation Research grant to further the company's development of a new ophthalmic screening device and testing protocols for the detection and diagnosis of diabetic retinopathy.

25 Jun 2010

New research suggests resveratrol may inhibit pathogenic blood vessel formation

Current research suggests that resveratrol, a naturally occurring compound found in red wine, grapes, blueberries, peanuts, and other plants, inhibits pathogenic new blood vessel growth.

25 Jun 2010

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment concept has demonstrated an amazing improvement in their treated patients' conditions. The ongoing clinical study shows the treatment's best case could reconstruct a patient's natural insulin production and even reverse later complications like kidney failure. Treated patients may have the chance to return to the normal activities non-diabetes sufferers take for granted.

24 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

AGTC, Icagen complete agreement for purchase and sale of patent rights

AGTC, a privately held company, and Icagen, Inc. today announced the completion of an agreement for the purchase and sale of certain patent rights between the companies. Icagen is transferring its rights to patents relating to the ion channel gene CNGB3, which has been linked to certain disorders of the eye. Under the terms of the agreement, Icagen has assigned ownership of the patents to AGTC, which intends to use the patented technology for gene therapy as a potential treatment for Achromatopsia, a severe form of daytime blindness.

24 Jun 2010

International Stem Cell congratulates ACT on the issuance of its recent patent

International Stem Cell Corporation, www.intlstemcell.com, a California-based biotechnology company focused on therapeutic and research products, congratulates Advanced Cell Technology, Inc. on the issuance of its recent patent, U.S. Patent Number 7,736,896, covering a method for producing retinal pigment epithelial cells.

24 Jun 2010

Debiotech, STMicroelectronics to showcase novel insulin "Jewel Pump" at ADA Congress

Debiotech and STMicroelectronics today announced that they will publicly showcase their novel insulin "Jewel Pump" at the Debiotech stand at the American Diabetes Association 70th Scientific Sessions (June 25-29) in Orlando, Florida.

24 Jun 2010

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.

23 Jun 2010

European drugmakers lead in making medicines available to developing world, Index says

European drug companies came out ahead of their U.S. counterparts in making medicines available to people in developing countries, but their lead is beginning to shrink, according to the Access to Medicines Index, released on Monday, Reuters reports (Kelland, 6/21).

23 Jun 2010

QLT reports final 24-month results from Phase II RADICAL study in patients with wet AMD

QLT Inc. today announced final 24-month results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with exudative (wet) age-related macular degeneration. The purpose of the study was to determine if Visudyne® combined with Lucentis® reduced retreatment rates compared with Lucentis monotherapy, while maintaining similar vision outcomes and an acceptable safety profile.

22 Jun 2010

APP Pharmaceuticals receives FDA approval to market Ganciclovir for Injection, USP

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Ganciclovir for Injection, USP. Ganciclovir for Injection, USP is therapeutically equivalent to the reference-listed drug Cytovene-IV, which is marketed by Roche Laboratories, Inc.

22 Jun 2010

Blindness News and Research

Rubella epidemic played a major role in shifting public attitudes toward abortion laws

Sunridge International delivers 60 PNT Units and 10,000 disposable rings to BV of China

UCSB, Sansum achieve milestone in JDRF funded Artificial Pancreas Project

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

In-school education programs can reduce obesity, other risk factors for type 2 diabetes: HEALTHY

HQC report presents different aspects of health care delivered in Saskatchewan hospitals

NKI awarded Phase II SBIR grant to develop new ophthalmic screening device for diabetic retinopathy

New research suggests resveratrol may inhibit pathogenic blood vessel formation

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

AGTC, Icagen complete agreement for purchase and sale of patent rights

International Stem Cell congratulates ACT on the issuance of its recent patent

Debiotech, STMicroelectronics to showcase novel insulin "Jewel Pump" at ADA Congress

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

European drugmakers lead in making medicines available to developing world, Index says

QLT reports final 24-month results from Phase II RADICAL study in patients with wet AMD

APP Pharmaceuticals receives FDA approval to market Ganciclovir for Injection, USP

Discoveries in study and manipulation of human ES cells win first prize in research competition

Blind cyclists to travel from Toronto to Collingwood in support of the Foundation Fighting Blindness

WSJ: Study on eye medicine reveals possible savings for Medicare

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News